A medicine hailed by doctors as 'life-saving' for Australians battling opioid dependence is about to disappear from the market, and experts warn it may be a sign of a much bigger shift unfolding across global healthcare.
US pharmaceutical company Indivior has confirmed it will stop supplying Sublocade in Australia from 31 December, ending access to a treatment many clinicians say has transformed the lives of patients recovering from opioid addiction.
